Unprecedented surrogate biomarkers are replacing clinical outcomes to secure accelerated drug approvals.
To expedite market access for paradigm-shifting therapies, regulatory agencies are accepting deep molecular markers or lifestyle-management surrogates rather than demanding traditional survival and functional endpoints.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The FDA granted accelerated approval for the breakthrough diabetes therapy using an unprecedented molecular biomarker rather than requiring standard clinical outcome measurements.
The FDA granted accelerated approval based on a surrogate, lifestyle-management endpoint (reducing raw cornstarch requirements) rather than definitive clinical metrics.
The drug secured accelerated approval based entirely on the surrogate biomarker of proteinuria reduction rather than clinical outcomes.
The FDA has dramatically accelerated the approval timeline in multiple myeloma by accepting a deep, molecular MRD-negativity marker as a surrogate endpoint.
Securing accelerated approval for Zenbexus was made possible by the FDA's acceptance of an unprecedented molecular surrogate biomarker to predict clinical efficacy.
By clearing Zenbexus based on MRD-negativity, the FDA has accepted an unprecedented molecular marker over standard functional endpoints to speed up oncology approvals.
Full approval rests on PFS and response-rate surrogates even though overall survival never statistically separates, confirming that surrogate endpoints now substitute for the survival outcome at the approval gate.
The FDA granted accelerated approval based on early molecular evidence from ctDNA resistance mutations rather than waiting for traditional imaging to confirm disease progression.